Colgate-Palmolive Company
$98.71+$1.83 (+1.9%)
Last close · Data as of Nov 20, 2026
- Market cap
- $68.1B
- P/E
- 31.9x
- EV / EBITDA
- 19.1x
- Revenue
- $20.4B
- Net margin
- 10.5%
- ROCE
- 44.7%
Price chart
Technical chartScreen technicals →+25.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +4.4%
- 3M
- +10.0%
- 6M
- +9.3%
- 1Y
- +25.2%
- 5Y
- +27.9%
52-week range
Day change +$1.83 (+1.9%) from $97 to $99 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in CL, bought on each weekday since 2021.
News & filings
What Colgate-Palmolive Company filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthReturn on capital employed of 44.7%.
Concerns (1)
- Net profit fell 26.2% in fiscal 2025.
- Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition.
Read moreShow less
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under the Colgate, Palmolive, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline, and Suavitel brands to a range of traditional and eCommerce retailers, wholesalers, and distributors, as well as dentists and skin health professionals. It also offers pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic pet products to help nutritionally support dogs and cats in different stages of health under the Hill's Prescription Diet brand; and a fresh pet food sold to pet specialty and other retailers in Australia under Prime100 brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
- Sector
- Consumer Defensive
- Shares outstanding
- 807.6M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $68.1B
- P/E
- 31.9x
- P/B
- 1261.0x
- EV / EBITDA
- 19.1x
- EV / Sales
- 3.7x
- P/S
- 3.3x
- 52-week high
- $100.99
- 52-week low
- $76.11
Profitability
- Operating margin
- 20.8%
- Net margin
- 10.5%
- EBITDA margin
- 19.4%
- ROE
- 3948.1%
- ROCE
- 44.7%
- ROA
- 13.1%
- Asset turnover
- 1.25
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $20.4B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 1.4%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 4.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -26.2%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $3.6B
Solvency
- Current ratio
- 0.83
- Debt / Equity
- 158.41
- Debt / Assets
- 0.52
- CFO / Net profit
- 1.97
- Cash / Market cap
- 1.9%
Where the revenue went
Of every $100 of FY2025 revenue, $10 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $8.1B |
| Revenue | Gross profit | $12.3B |
| Gross profit | Selling, general and administrative | $7.9B |
| Gross profit | Other operating expenses | $115.0M |
| Gross profit | Operating income | $4.2B |
| Operating income | Pretax income | $3.1B |
| Operating income | Interest and other expense | $1.2B |
| Pretax income | Tax and other | $927.0M |
| Pretax income | Net income | $2.1B |
Revenue and net profit
Revenue grew 1.4% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $18.0B | $1.8B |
| FY2023 | $19.5B | $2.3B |
| FY2024 | $20.1B | $2.9B |
| FY2025 | $20.4B | $2.1B |
Cash flows
FY2025: $4.2B from operations, $3.6B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $2.6B | $1.9B |
| FY2023 | $3.7B | $3.0B |
| FY2024 | $4.1B | $3.5B |
| FY2025 | $4.2B | $3.6B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $20.4B+1.4%1Y
- EBITDA
- $4.0B-18.5%1Y
- Net profit
- $2.1B-26.2%1Y
- Cash from operations
- $4.2B+2.2%1Y
- Free cash flow
- $3.6B+2.5%1Y
- Revenue CAGR, 3Y
- 4.3%
- Net profit CAGR, 3Y
- 6.1%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $20.4B | $4.0B | $2.1B | $3.6B | 3948.1% | +1.4% | -26.2% |
Monthly returns
Month-by-month returns of CL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $16.3B |
| Current assets | $5.7B |
| Non-current assets | $10.6B |
| Liabilities | $16.0B |
| Current liabilities | $6.9B |
| Non-current liabilities | $9.1B |
| Equity | $365.0M |
| Paid-in capital | $4.3B |
| Retained earnings | $26.6B |
| Treasury stock | $28.4B |
| Minority interest | $311.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Consumer Defensive companies placed by value, growth and quality; CL highlighted.
P/E against peers
CL trades at 31.9x earnings against a peer median of 34.6x.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Colgate-Palmolive CompanyCLthis company | $68.1B | 31.9x | 1261.0x | 3948.1% | 19.1x |
| Monster Beverage CorporationMNST | $86.6B | 45.4x | 10.5x | 23.1% | 33.2x |
| Mondelez International, Inc.MDLZ | $78.3B | 31.9x | 3.0x | 9.5% | 19.7x |
| Target CorporationTGT | $56.3B | 15.2x | 3.5x | 22.9% | 8.5x |
| Keurig Dr Pepper Inc.KDP | $40.9B | 19.7x | 1.6x | 8.1% | 13.4x |
| Coca-Cola Europacific Partners PLCCCEP | $40.7B | 21.0x | 5.2x | 24.8% | 13.4x |
| Archer-Daniels-Midland CompanyADM | $40.2B | 37.3x | 1.8x | 4.7% | 16.1x |
| The Kroger Co.KR | $38.4B | 37.8x | 6.5x | 17.1% | 10.4x |
| The Hershey CompanyHSY | $37.1B | 42.0x | 8.0x | 19.0% | 21.6x |
| Peer median | — | 34.6x | 4.3x | 18.1% | 14.7x |
Year-to-date ROI
CL since 1 January, against earlier years.
Historical volatility
CL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 20.1% |
| FY2023 | 21.0% |
| FY2024 | 21.5% |
| FY2025 | 20.8% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $20.4B |
| Cost of revenueCost Of Revenue | $8.1B |
| Gross profitGross Profit | $12.3B |
| Operating expensesOperating Expense | $8.0B |
| Selling, general and administrativeSelling General And Administration | $7.9B |
| Other operating expensesOther Operating Expenses | — |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $78.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $78.0M |
| Amortization | $78.0M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $78.0M |
| Total expensesTotal Expenses | $16.1B |
| Operating incomeOperating Income | $4.2B |
| Interest and other | |
| Pretax incomePretax Income | $3.1B |
| TaxTax Provision | $798.0M |
| Net incomeNet Income | $2.1B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $16.3B |
| Current assetsCurrent Assets | $5.7B |
| Non-current assetsTotal Non Current Assets | $10.6B |
| LiabilitiesTotal Liabilities Net Minority Interest | $16.0B |
| Current liabilitiesCurrent Liabilities | $6.9B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $9.1B |
| EquityTotal Equity Gross Minority Interest | $365.0M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $4.2B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $4.2B |
| Net income, continuing operationsNet Income From Continuing Operations | $2.3B |
| Depreciation and amortisationDepreciation And Amortization | $630.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $630.0M |
| Stock-based compensationStock Based Compensation | $155.0M |
| Deferred taxDeferred Tax | -$109.0M |
| Deferred income taxDeferred Income Tax | -$109.0M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | — |
| Asset impairmentAsset Impairment Charge | $919.0M |
| Pension and employee benefit expensePension And Employee Benefit Expense | — |
| Change in working capitalChange In Working Capital | $284.0M |
| Other non-cash itemsOther Non Cash Items | $58.0M |
| Investing cash flowInvesting Cash Flow | -$817.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$817.0M |
| Capital expenditureCapital Expenditure | -$564.0M |
| Capital expenditure (reported)Capital Expenditure Reported | -$564.0M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | — |
| AcquisitionsPurchase Of Business | -$293.0M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$293.0M |
| Purchase of investmentsPurchase Of Investment | -$698.0M |
| Sale of investmentsSale Of Investment | $752.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | $54.0M |
| Other investing changesNet Other Investing Changes | -$14.0M |
| Financing cash flowFinancing Cash Flow | -$3.3B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$3.3B |
| Debt issuedIssuance Of Debt | $1.2B |
| Debt repaidRepayment Of Debt | -$655.0M |
| Net debt issuedNet Issuance Payments Of Debt | -$456.0M |
| Net short-term debt issuedNet Short Term Debt Issuance | -$989.0M |
| Long-term debt issuedLong Term Debt Issuance | $1.2B |
| Long-term debt repaidLong Term Debt Payments | -$655.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | $533.0M |
| Net common stock issuedNet Common Stock Issuance | -$1.2B |
| Common stock repurchasedCommon Stock Payments | -$1.2B |
| Share buybacksRepurchase Of Capital Stock | -$1.2B |
| Stock options exercisedProceeds From Stock Option Exercised | $101.0M |
| Dividends paidCash Dividends Paid | -$1.8B |
| Common dividends paidCommon Stock Dividend Paid | -$1.8B |
| Other financing chargesNet Other Financing Charges | $132.0M |
| Change in cashChanges In Cash | $125.0M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 6,700.0% |
| Cash at the start of the yearBeginning Cash Position | $1.1B |
| Cash at the end of the yearEnd Cash Position | $1.3B |
| Free cash flowFree Cash Flow | $3.6B |
| Supplemental |
Learn while you research
Academy chapters picked for Colgate-Palmolive Company and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Valuation Multiples ExplainedThis stock trades at a P/E of 31.9, learn when high multiples are justified.6 min read
- 03 Leverage RatiosDebt/Equity of 158.41 is elevated, understand what that means for solvency.6 min read
- 04 Cyclical vs Defensive StocksConsumer staples behave defensively across the business cycle.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read